Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(165 productos)
- Bcr-Abl(117 productos)
- EGFR(572 productos)
- FAK(72 productos)
- FLT(86 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(178 productos)
- JAK(244 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(56 productos)
- VDA(2 productos)
- VEGFR(239 productos)
Mostrar 6 subcategorías más
Se han encontrado 2329 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Fórmula:C17H15N7O5SForma y color:SolidPeso molecular:429.41LCK degrader-2
LCKdegrader-2 (Compound 17) is a Lck molecular glue degrader. It is applicable for research in cancers such as acute lymphoblastic leukemia (ALL).Forma y color:Odour SolidEGFR/BRAFV600E-IN-4
EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.Fórmula:C22H16N4OSForma y color:SolidPeso molecular:384.45Povorcitinib phosphate
CAS:Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.Fórmula:C23H25F5N7O5PPureza:99.57%Forma y color:SolidPeso molecular:605.45Ref: TM-T39113L
1mg46,00€5mg96,00€10mg145,00€25mg236,00€50mg339,00€100mg460,00€200mg622,00€1mL*10mM (DMSO)128,00€FGFRs-IN-1
FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.Fórmula:C28H26Cl2N4O3Forma y color:SolidPeso molecular:537.44JAK3-IN-14
CAS:JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.Fórmula:C18H13N3OPureza:98.29%Forma y color:SoildPeso molecular:287.32Ref: TM-T67754
1mg167,00€5mg409,00€10mg595,00€25mg888,00€50mg1.234,00€100mg1.665,00€1mL*10mM (DMSO)358,00€MY-1576
MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.Fórmula:C25H29ClN8O2Forma y color:SolidPeso molecular:509FGFR1 inhibitor 7
FGFR1 Inhibitor 7 (compound 5), a potent FGFR1 tyrosine kinase inhibitor, exhibits an IC50 of 0.33 nM against its target and demonstrates broad-spectrumFórmula:C25H16ClNO4Pureza:98%Forma y color:SolidPeso molecular:429.85Trastuzumab rezetecan
CAS:Trastuzumab rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) targeting HER2. It is composed of a humanized anti-HER2 antibody, a cleavable linker MC-Gly-Gly-Phe-Gly, and an effective payload of the topoisomerase I inhibitor Rezetecán. Trastuzumab rezetecan is utilized in the research of HER2-positive breast cancer.Forma y color:LiquidFGFR1/VEGFR2-IN-1
FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].
Fórmula:C26H27N4O6PPureza:98%Forma y color:SolidPeso molecular:522.49Syk-IN-7
Syk-IN-7 (compound 17) acts as an inhibitor of spleen tyrosine kinase (SYK) [1].Fórmula:C26H31N9O4Pureza:98%Forma y color:SolidPeso molecular:533.58Itacitinib adipate
CAS:Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.Fórmula:C32H33F4N9O5Forma y color:SolidPeso molecular:699.66Poseltinib
CAS:Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.Fórmula:C26H26N6O3Pureza:99.98%Forma y color:SolidPeso molecular:470.52Ref: TM-T4413
2mg34,00€5mg49,00€10mg75,00€25mg146,00€50mg260,00€100mg409,00€200mg590,00€1mL*10mM (DMSO)50,00€DTP3
CAS:DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Fórmula:C26H35N7O5Forma y color:SolidPeso molecular:525.6Lestaurtinib
CAS:Lestaurtinib (CEP 701) is a FLT3 inhibitor that inhibits the phosphorylation of RPTKs and can be used to study leukemia.Fórmula:C26H21N3O4Pureza:99.17%Forma y color:Off-White SolidPeso molecular:439.46A-770041
CAS:A-770041 is an Lck inhibitor, YZ inhibits the production of IL-2 stimulated by concanavalin A in whole blood, and can prevent cardiac allograft rejection.Fórmula:C34H39N9O3Pureza:99.23% - 99.86%Forma y color:SolidPeso molecular:621.73Ref: TM-T14074
2mg70,00€5mg104,00€10mg170,00€25mg384,00€50mg652,00€100mg1.018,00€200mg1.350,00€1mL*10mM (DMSO)142,00€BI-3663
CAS:BI-3663 is a selective PTK2/FAK PROTAC with cereblon ligands, degrading PTK2 (IC50: 18 nM), and shows anti-cancer properties.Fórmula:C44H42F3N7O12Pureza:98%Forma y color:SolidPeso molecular:917.84Flurandrenolide
CAS:Flurandrenolide is a corticosteroid with anti-inflammatory effects that activates EGFR (EC50=23 nM).Fórmula:C24H33FO6Forma y color:Crystals From Acetone + Hexane SolidPeso molecular:436.51CHZ868
CAS:CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.Fórmula:C22H19F2N5O2Pureza:99.38%Forma y color:SolidPeso molecular:423.42BPR1K871
CAS:BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values ofFórmula:C25H28ClN7O2SForma y color:SolidPeso molecular:526.05
